港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

礼邦医药-B

32.460

-0.660-1.99%

成交量：28.27万

成交额：913.02万

市值：112.96亿

市盈率：-10.57

高：34.800

开：32.780

低：31.620

收：33.120

52周最高：46.820

52周最低：22.720

股本：3.48亿

香港流通股本：2.36亿

量比：1.03

换手率：0.12%

股息：- -

股息率：- -

每股收益(LYR):-3.071

净资产收益率：--

总资产收益率：-33.01%

市净率：19.25

市盈率(LYR):-10.57

市销率: 316.99

数据加载中...

总览公司新闻资讯公告

财报前瞻｜礼邦医药-B本季度预测数据未披露，机构观点待明朗

获纳入恒生综指礼邦医药-B(09637.HK)有望跻身港股通

礼邦医药-B：Tencent Holdings Limited增持，好仓比例升至10.0%

礼邦医药-B（09637）临时股东会通过审计师委任及股份发行、回购授权

礼邦医药-B（09637）董事会定于2026年8月26日审议中期业绩

【券商聚焦】华泰证券首予礼邦医药（09637）买入评级指肾病管线卡位优

礼邦医药－Ｂ(09637)股价下跌5.287%，现价港币$34.04

阿斯达克财经

礼邦医药－Ｂ(09637)股价上升9.18%，现价港币$35.68

阿斯达克财经

《股市简讯》中国礼邦医药涨6.2%创近六周新高，高磷血症药物上市申请获受理

礼邦医药(09637.HK)AP301胶囊相关新药上市申请获受理

阿斯达克财经

礼邦医药-B（09637）高磷血症新药AP301获国家药监局受理上市申请

礼邦医药-B(09637.HK)：AP301胶囊治疗接受透析的慢性肾脏病患者高磷血症新药上市申请获国家药品监督管理局受理

中国药监局受理礼邦医药AP301胶囊新药申请，用于治疗CKD透析患者高磷血症

《股市简讯》中国生物科技公司礼邦医药涨2.8%，料上半年亏损同比收窄至多25%

礼邦医药-B(09637.HK)盈喜：上半年收入暴涨超7倍，亏损显著收窄，成长潜力备受关注

礼邦医药(09637.HK)料中期亏损收窄至最多1.78亿人币

阿斯达克财经

礼邦医药-B发布2026年中期盈利预喜：收入同比大增逾7倍，亏损收窄

礼邦医药－Ｂ(09637)股价下跌6.145%，现价港币$31.16

阿斯达克财经

礼邦医药-B发布2026年7月股份变动月报，H股注册股本增至2.36亿元

港股异动 | FSGS赛道热度再起，礼邦医药-B(09637)大涨超15% 机构指其有望进入港股通

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/09637/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","market":"HK","secType":"STK","nameCN":"礼邦医药-B","latestPrice":32.46,"timestamp":1787558899372,"preClose":33.12,"halted":0,"volume":282700,"delay":0,"changeRate":-0.019927536231883956,"floatShares":236000000,"shares":348000000,"eps":-3.071284,"marketStatus":"未开盘","change":-0.66,"latestTime":"08-24 16:08:19","open":32.78,"high":34.8,"low":31.62,"amount":9130235,"amplitude":0.096014,"askPrice":32.46,"askSize":5500,"bidPrice":32.24,"bidSize":2600,"shortable":0,"etf":0,"ttmEps":-2.384,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787621400000},"marketStatusCode":0,"adr":0,"listingDate":1782662400000,"exchange":"SEHK","adjPreClose":33.12,"openAndCloseTimeList":[[1787535000000,1787544000000],[1787547600000,1787558400000]],"volumeRatio":1.0289451326126249,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","floatShares":236000000,"roa":"-33.01%","roe":"--","lyrEps":-3.071284,"volumeRatio":1.0289451326126249,"shares":348000000,"dividePrice":0,"high":34.8,"amplitude":0.096014,"preClose":33.12,"low":31.62,"week52Low":22.72,"pbRate":"19.25","psRate":"316.99","week52High":46.82,"institutionHeld":0,"latestPrice":32.46,"committee":-0.358025,"eps":-3.071284,"divideRate":0,"volume":282700,"delay":0,"ttmEps":-2.384,"open":32.78,"prevYearClose":22.6,"prevWeekClose":33.12,"prevMonthClose":27.24,"prevQuarterClose":45.92,"fiveDayClose":33.74,"twentyDayClose":29.14,"sixtyDayClose":22.6,"earningDate":1787673600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09637\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"09637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09637\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1786723200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09637","date":"2026-08-24","current":-13.615772,"percent":0.410256,"low":-18.066068,"twenty":-13.058353,"median":-11.768252,"eighty":-10.939493,"high":-8.87585,"avg":-12.206412,"sd":1.7771,"marketCap":11031603418},"quantilePoints":[{"date":"2026-06-26","current":-8.87585,"twenty":-8.87585,"median":-8.87585,"eighty":-8.87585,"marketCap":7680660420},{"date":"2026-07-03","current":-11.883178,"twenty":-18.03155,"median":-11.883178,"eighty":-9.78101,"marketCap":10290725554},{"date":"2026-07-10","current":-12.164969,"twenty":-13.966639,"median":-11.847257,"eighty":-11.12129,"marketCap":10521825071},{"date":"2026-07-17","current":-10.947234,"twenty":-12.322489,"median":-11.455859,"eighty":-10.783874,"marketCap":9502268378},{"date":"2026-07-24","current":-11.320561,"twenty":-11.939536,"median":-11.377389,"eighty":-10.939493,"marketCap":9828526520},{"date":"2026-07-31","current":-10.642718,"twenty":-11.840073,"median":-11.194259,"eighty":-10.78337,"marketCap":9257574772},{"date":"2026-08-07","current":-12.743391,"twenty":-12.396338,"median":-11.399787,"eighty":-10.889159,"marketCap":11106370909},{"date":"2026-08-14","current":-13.03884,"twenty":-12.987078,"median":-11.462395,"eighty":-10.903987,"marketCap":11378252693},{"date":"2026-08-21","current":-12.870195,"twenty":-13.077865,"median":-11.725167,"eighty":-10.931752,"marketCap":11255905890},{"date":"2026-08-24","current":-12.618266,"twenty":-13.058353,"median":-11.768252,"eighty":-10.939493,"marketCap":11031603418}],"updateTime":1787617578611},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09637\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1158482414","title":"财报前瞻｜礼邦医药-B本季度预测数据未披露，机构观点待明朗","url":"https://stock-news.laohu8.com/highlight/detail?id=1158482414","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1158482414?lang=zh_cn&edition=fundamental","pubTime":"2026-08-19 09:10","pubTimestamp":1787101826,"startTime":"0","endTime":"0","summary":"礼邦医药-B将于2026年08月26日发布最新季度财报，市场对关键指标共识尚未形成，投资者关注度集中在现金流与商业化推进节奏。由于未获得权威一致预期及公司层面的本季度前瞻披露，关于本季度的营收、毛利率、净利润或净利率、调整后每股收益的预测信息暂无可用数据。市场在本季度更关注期间费用率的变化轨迹，其中销售费用与研发费用的配置会直接影响利润端的弹性。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜礼邦医药-B本季度预测数据未披露，机构观点待明朗","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661326717","title":"获纳入恒生综指 礼邦医药-B(09637.HK)有望跻身港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=2661326717","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661326717?lang=zh_cn&edition=fundamental","pubTime":"2026-08-21 19:26","pubTimestamp":1787311583,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","09939","09637","BK1191","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164312475","title":"礼邦医药-B：Tencent Holdings Limited增持，好仓比例升至10.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164312475","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164312475?lang=zh_cn&edition=fundamental","pubTime":"2026-08-21 17:11","pubTimestamp":1787303498,"startTime":"0","endTime":"0","summary":"Tencent Holdings Limited于2026年8月17日以每股均价32.3366港元买入礼邦医药-B股份3.10万股，涉资约100.24万港元。Tencent Holdings Limited此次增持前持有礼邦医药-B好仓2353.56万股，占比9.99%；增持后持股量为2356.66万股，好仓比例升至10.0%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198136493","title":"礼邦医药-B（09637）临时股东会通过审计师委任及股份发行、回购授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1198136493","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198136493?lang=zh_cn&edition=fundamental","pubTime":"2026-08-14 18:22","pubTimestamp":1786702925,"startTime":"0","endTime":"0","summary":"8月14日，礼邦医药-B公布其于2026年8月14日举行的临时股东会投票结果，全部议案均获股东高票通过。此次会议共有348,365,531股具表决权股份获准参与投票，公司董事会成员全部以现场或电子方式出席会议。公告同时披露，截至EGM召开日，公司无任何库存股份或待注销的回购股份，亦不存在股东受限投票或需放弃投票的情形。截至公告日，礼邦医药-B董事会由4名执行董事、1名非执行董事及3名独立非执行董事组成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178604628","title":"礼邦医药-B（09637）董事会定于2026年8月26日审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1178604628","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178604628?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 19:42","pubTimestamp":1786621361,"startTime":"0","endTime":"0","summary":"礼邦医药-B（09637）8月13日公告称，公司董事会将于2026年8月26日（星期三）召开会议，届时将审议并批准集团截至2026年6月30日止六个月的中期业绩及其发布事宜。公告显示，截至公告日期，公司董事会由8名成员组成，包括4名执行董事──Gavin Guoyao Xia博士、Jin Tian医生、汪昀女士及张华丁博士；1名非执行董事鲁安博士；以及3名独立非执行董事徐润红博士、Zhui Chen博士及梁智维先生。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659135560","title":"【券商聚焦】华泰证券首予礼邦医药（09637）买入评级 指肾病管线卡位优","url":"https://stock-news.laohu8.com/highlight/detail?id=2659135560","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659135560?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 13:52","pubTimestamp":1786600358,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券发布研报指，首次覆盖礼邦医药-B 并给予“买入”评级，目标价51.86港元。据CIC数据，2025年全球高磷血症药物市场规模达18亿美元，2035年有望达64亿美元，且全球仅有这两个创新管线。2023年公司与罗氏达成独家商业化合作，华泰预计美信罗有望于2034年在中国实现约10亿元人民币销售峰值，考虑中国长效制剂渗透率提升、成熟商业化团队支撑以及罗氏供应瓶颈解决。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988115","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","159938","09939","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659182479","title":"礼邦医药－Ｂ(09637)股价下跌5.287%，现价港币$34.04","url":"https://stock-news.laohu8.com/highlight/detail?id=2659182479","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659182479?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 10:05","pubTimestamp":1786586700,"startTime":"0","endTime":"0","summary":"[下跌股]礼邦医药－Ｂ(09637) 股价在上午10:05比前收市价下跌5.287%，现股价为港币$34.04。至目前为止，今日最高价为$35.8，而最低价为$34.04。总成交量为2.37万股，总成交金额为港币$82.817万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD260813584/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD260813584/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","09939","BK1191","BK1161","159938","09637","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658602303","title":"礼邦医药－Ｂ(09637)股价上升9.18%，现价港币$35.68","url":"https://stock-news.laohu8.com/highlight/detail?id=2658602303","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658602303?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 11:57","pubTimestamp":1786334220,"startTime":"0","endTime":"0","summary":"[上升股]礼邦医药－Ｂ(09637) 股价在上午11:57比前收市价上升9.18%，现股价为港币$35.68。至目前为止，今日最高价为$35.68，而最低价为$32.76。总成交量为21.5万股，总成交金额为港币$735.053万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2608101785/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2608101785/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK1574","BK1161","159938","09939","BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658960979","title":"《股市简讯》中国礼邦医药涨6.2%创近六周新高，高磷血症药物上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2658960979","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658960979?lang=zh_cn&edition=fundamental","pubTime":"2026-08-10 10:14","pubTimestamp":1786328040,"startTime":"0","endTime":"0","summary":"《股市简讯》中国礼邦医药涨6.2%创近六周新高，高磷血症药物上市申请获受理* 中国生物科技公司--礼邦医药9637.HK周一早盘高开0.2%，随后涨幅扩大至6.2%，创7月2日以来新高。* 该公司此前公告称，AP301胶囊用于治疗接受维持性透析的慢性肾脏病患者高磷血症的新药上市申请获中国国家药监局受理。高磷血症是接受透析的慢性肾脏病患者常见的并发症。* 恒⽣⽣物科技指数.HSBIO盘中一度劲升4.2%。（完）更多股市简讯请点选CN-CMN-HOT","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL4T44704Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657614343","title":"礼邦医药(09637.HK)AP301胶囊相关新药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2657614343","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657614343?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 17:44","pubTimestamp":1786095840,"startTime":"0","endTime":"0","summary":"礼邦医药-B(09637.HK) 公布，其管线AP301胶囊(一款新型口服含铁磷结合剂)用于治疗接受维持性透析的慢性肾脏病患者高磷血症的新药上市申请，今日(7日)获国家药监局正式受理。该新药上市申请主要基于AP301在中国完成的关键III期临床试验RESPOND-1的结果及其他累积临床资料。(ha/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260618090434961_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260618090434961_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1537199/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1537199/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","09637","BK1574","BK1161","159938","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132620884","title":"礼邦医药-B（09637）高磷血症新药AP301获国家药监局受理上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1132620884","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132620884?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 17:30","pubTimestamp":1786095045,"startTime":"0","endTime":"0","summary":"2026年8月7日，礼邦医药-B发布自愿公告称，公司自主研发的口服含铁磷结合剂AP301胶囊用于治疗接受维持性透析的慢性肾脏病患者高磷血症的新药上市申请已获中国国家药品监督管理局正式受理。该申请基于在中国完成的关键III期临床试验RESPOND-1结果及其他临床数据。RESPOND-1试验在中国50家中心开展，共入组474名高磷血症透析患者，按3:1随机分配至AP301组和阳性对照药碳酸司维拉姆组，治疗周期52周。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657011619","title":"礼邦医药-B(09637.HK)：AP301胶囊治疗接受透析的慢性肾脏病患者高磷血症新药上市申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2657011619","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657011619?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 17:26","pubTimestamp":1786094817,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1574","09939","BK1161","BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123987914","title":"中国药监局受理礼邦医药AP301胶囊新药申请，用于治疗CKD透析患者高磷血症","url":"https://stock-news.laohu8.com/highlight/detail?id=1123987914","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123987914?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 17:26","pubTimestamp":1786094775,"startTime":"0","endTime":"0","summary":"礼邦医药（Alebund Pharmaceuticals，江苏）宣布，国家药品监督管理局（NMPA）已正式受理其AP301胶囊的新药上市申请（NDA）。该药针对慢性肾病患者透析过程中出现的高磷血症。这一里程碑事件，标志着其研发取得关键进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657660937","title":"《股市简讯》中国生物科技公司礼邦医药涨2.8%，料上半年亏损同比收窄至多25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657660937","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657660937?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 09:59","pubTimestamp":1786067988,"startTime":"0","endTime":"0","summary":"《股市简讯》中国生物科技公司礼邦医药涨2.8%，料上半年亏损同比收窄至多25%* 中国生物科技公司--礼邦医药9637.HK周五早盘升2.8%。* 该公司此前公告称，预计上半年期内亏损同比收窄15-25%至1.58-1.78亿元人民币，主要由于就AP306与R1 Therapeutics订立的许可及股权协议项下确认的许可收入及美信罗销售增长带动收入增加；若干股份的赎回责任已于上市前终止（属一次性因素），报告期内不再计提相关利息，令亏损收窄。* 恒⽣⽣物科技指数.HSBIO盘中一度升2%。（完）更多股市简讯请点选CN-CMN-HOT","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL4S44404H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657684479","title":"礼邦医药-B(09637.HK)盈喜：上半年收入暴涨超7倍，亏损显著收窄，成长潜力备受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2657684479","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657684479?lang=zh_cn&edition=fundamental","pubTime":"2026-08-06 17:59","pubTimestamp":1786010361,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1161","09939","BK1191","BK1574","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657689197","title":"礼邦医药(09637.HK)料中期亏损收窄至最多1.78亿人币","url":"https://stock-news.laohu8.com/highlight/detail?id=2657689197","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657689197?lang=zh_cn&edition=fundamental","pubTime":"2026-08-06 17:06","pubTimestamp":1786007160,"startTime":"0","endTime":"0","summary":"礼邦医药-B(09637.HK) 发盈喜，预期截至2026年6月30日止中期收入将介乎约1.03亿至1.06亿元人民币，按年增长约750%至775%；期内录亏损约1.58亿至1.78亿元人民币，较去年同期的2.1亿元人民币亏损收窄。礼邦医药解释，亏损收窄则主要由于公司若干股份的赎回责任已于上市前终止，属一次性因素，期内不再计提相关利息；而收入显著增长主要由于就AP306与R1 Therapeutics订立的许可及股权协议项下确认的许可收入，以及美信罗销售增长所带动。(gc/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260618090434445_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260618090434445_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1536989/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1536989/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1191","BK1515","09637","09939","BK1161","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108879461","title":"礼邦医药-B发布2026年中期盈利预喜：收入同比大增逾7倍，亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1108879461","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108879461?lang=zh_cn&edition=fundamental","pubTime":"2026-08-06 16:42","pubTimestamp":1786005722,"startTime":"0","endTime":"0","summary":"礼邦医药（江苏）股份有限公司8月6日公告称，根据董事会对截至2026年6月30日止六个月未经审阅的合并管理账目初步评估，预期本期收入约为1.03亿元至1.06亿元，较去年同期的12.1百万元增长约750%至775%。董事会表示，收入大幅增长主要源于AP306与R1 Therapeutics签订许可及股权协议确认的许可收入，以及美信罗销售增加；亏损收窄则受益于上市前若干股份赎回责任终止，报告期内不再计提相关利息。公司计划于2026年8月公布中期业绩。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657060215","title":"礼邦医药－Ｂ(09637)股价下跌6.145%，现价港币$31.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2657060215","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657060215?lang=zh_cn&edition=fundamental","pubTime":"2026-08-06 11:59","pubTimestamp":1785988740,"startTime":"0","endTime":"0","summary":"[下跌股]礼邦医药－Ｂ(09637) 股价在上午11:59比前收市价下跌6.145%，现股价为港币$31.16。至目前为止，今日最高价为$33.8，而最低价为$31.16。总成交量为9.282万股，总成交金额为港币$304.114万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2608062824/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2608062824/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","09939","BK1161","BK1515","159938","09637","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161461460","title":"礼邦医药-B发布2026年7月股份变动月报，H股注册股本增至2.36亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161461460","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161461460?lang=zh_cn&edition=fundamental","pubTime":"2026-08-05 16:48","pubTimestamp":1785919721,"startTime":"0","endTime":"0","summary":"礼邦医药(江蘇)股份有限公司于2026年8月5日公布截至2026年7月31日的股份变动月报。报告期内，公司H股注册股本由2.27亿元增至2.36亿元，增加8,513,300股；内资股保持不变，维持1.13亿元。截至本月末，公司注册股本合计达3.48亿元，较上月增长约8,513,300股。本报告期内，公司因于2026年7月29日悉数行使超额配股权而完成相应H股增发，发行价格为每股22.6港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657519476","title":"港股异动 | FSGS赛道热度再起，礼邦医药-B(09637)大涨超15% 机构指其有望进入港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=2657519476","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657519476?lang=zh_cn&edition=fundamental","pubTime":"2026-08-05 15:51","pubTimestamp":1785916293,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月5日，礼邦医药-B大幅走高，盘中涨超15%。截至发稿，涨13.07%，报33.22港元，成交额2921.2万港元。今年4月，FILSPARI获FDA批准成为首个FSGS治疗药物，这一长期缺药的肾病适应症正被资本市场重新定价。FSGS的热度也让市场重新审视礼邦医药在同一适应症上的布局。该行测算，49只股票有望纳入港股通，其中包括礼邦医药。据悉，获纳入港股通有利于扩大公司投资者基础，潜在提高H股交易流动性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","FLHK","09939","FSGS","KCAI","VXUS","BK1161","09637","159938","BK1191","BK1515","BK1574","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":67,"code":"91000000","status":"200"}]}}